Xilio Therapeutics (XLO) Total Debt (2020 - 2023)

Xilio Therapeutics has disclosed Total Debt across 4 years of filings, most recently posting $3.3 million for Q4 2023.

• In Q4 2023, Total Debt fell 66.28% year-over-year to $3.3 million; the TTM figure through Dec 2023 stood at $3.3 million (down 66.28% YoY), while the FY2023 annual figure was $3.3 million, down 66.28% from the prior year.
• Total Debt came in at $3.3 million for Q4 2023 at Xilio Therapeutics, down from $5.0 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $9.8 million in Q4 2022 to a low of $3.3 million in Q4 2023.
• Average Total Debt over 4 years is $8.3 million, with a median of $9.6 million recorded in 2021.
• Year-over-year, Total Debt increased 2.12% in 2022 and plunged 66.28% in 2023.
• Over 4 years, Total Debt stood at $9.7 million in 2020, then fell by 1.2% to $9.6 million in 2021, then climbed by 2.12% to $9.8 million in 2022, then sank by 66.28% to $3.3 million in 2023.
• Per Business Quant data, the three most recent Total Debt figures were $3.3 million in Q4 2023, $5.0 million in Q3 2023, and $7.1 million in Q2 2023.